ACI Formulations Past Earnings Performance
Past criteria checks 4/6
ACI Formulations has been growing earnings at an average annual rate of 20.3%, while the Chemicals industry saw earnings growing at 6.1% annually. Revenues have been growing at an average rate of 7.4% per year. ACI Formulations's return on equity is 8.8%, and it has net margins of 5.7%.
Key information
20.3%
Earnings growth rate
20.3%
EPS growth rate
| Chemicals Industry Growth | 6.1% |
| Revenue growth rate | 7.4% |
| Return on equity | 8.8% |
| Net Margin | 5.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ACI Formulations makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,975 | 283 | 856 | 0 |
| 31 Dec 23 | 5,049 | 249 | 845 | 0 |
| 30 Sep 23 | 5,097 | 239 | 843 | 0 |
| 30 Jun 23 | 4,960 | 235 | 833 | 0 |
| 31 Mar 23 | 4,834 | 249 | 817 | 0 |
| 31 Dec 22 | 4,683 | 258 | 816 | 0 |
| 30 Sep 22 | 4,521 | 263 | 799 | 0 |
| 30 Jun 22 | 4,247 | 243 | 774 | 0 |
| 31 Mar 22 | 4,298 | 279 | 775 | 0 |
| 31 Dec 21 | 4,242 | 277 | 762 | 0 |
| 30 Sep 21 | 4,038 | 247 | 743 | 0 |
| 30 Jun 21 | 3,865 | 213 | 714 | 0 |
| 31 Mar 21 | 3,841 | 192 | 646 | 0 |
| 31 Dec 20 | 3,682 | 152 | 698 | 0 |
| 30 Sep 20 | 3,520 | 105 | 702 | 0 |
| 30 Jun 20 | 3,424 | 93 | 727 | 0 |
| 31 Mar 20 | 3,385 | 76 | 794 | 0 |
| 31 Dec 19 | 3,539 | 83 | 786 | 0 |
| 30 Sep 19 | 3,854 | 118 | 783 | 0 |
| 30 Jun 19 | 4,052 | 129 | 810 | 0 |
| 31 Mar 19 | 4,087 | 130 | 727 | 0 |
| 31 Dec 18 | 4,364 | 115 | 720 | 0 |
| 30 Sep 18 | 4,438 | 130 | 761 | 0 |
| 30 Jun 18 | 4,153 | 117 | 700 | 0 |
| 31 Mar 18 | 4,015 | 139 | 771 | 0 |
| 31 Dec 17 | 3,712 | 193 | 697 | 0 |
| 30 Sep 17 | 3,632 | 238 | 653 | 0 |
| 30 Jun 17 | 3,663 | 263 | 638 | 0 |
| 31 Dec 16 | 3,160 | 228 | 589 | 0 |
| 30 Sep 16 | 3,056 | 202 | 529 | 0 |
| 30 Jun 16 | 3,093 | 211 | 515 | 0 |
| 30 Sep 15 | 2,771 | 190 | 424 | 0 |
| 30 Jun 15 | 2,725 | 184 | 437 | 0 |
| 31 Mar 15 | 2,901 | 194 | 443 | 0 |
| 31 Dec 14 | 2,912 | 186 | 435 | 0 |
| 30 Sep 14 | 3,696 | 208 | 561 | 0 |
| 30 Jun 14 | 2,560 | 153 | 383 | 0 |
| 31 Mar 14 | 2,421 | 137 | 341 | 5 |
| 31 Dec 13 | 2,340 | 129 | 356 | 0 |
| 30 Sep 13 | 1,352 | 80 | 222 | 0 |
| 30 Jun 13 | 2,303 | 139 | 328 | 0 |
Quality Earnings: ACIFORMULA has high quality earnings.
Growing Profit Margin: ACIFORMULA's current net profit margins (5.7%) are higher than last year (5.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACIFORMULA's earnings have grown significantly by 20.3% per year over the past 5 years.
Accelerating Growth: ACIFORMULA's earnings growth over the past year (13.7%) is below its 5-year average (20.3% per year).
Earnings vs Industry: ACIFORMULA earnings growth over the past year (13.7%) exceeded the Chemicals industry -3.5%.
Return on Equity
High ROE: ACIFORMULA's Return on Equity (8.8%) is considered low.